From bevacizumab to tasquinimod: Angiogenesis as a therapeutic target in prostate cancer

Cancer Journal (United States)

Volumn 19, Issue 1, 2013, Pages 99-106

  Schweizer, Michael T ^a   Carducci, Michael A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

aflibercept; angiogenesis; bevacizumab; cabozantinib; itraconazole; lenalidomide; prostate cancer; sunitinib; Tasquinimod; thalidomide

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CABOZANTINIB; CALGRANULIN B; CD135 ANTIGEN; CEDIRANIB; CYTOTOXIC AGENT; DOCETAXEL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOMODULATING AGENT; ITRACONAZOLE; LENALIDOMIDE; MITOXANTRONE; PLACEBO; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; POMALIDOMIDE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TASQUINIMOD; THALIDOMIDE; THROMBOSPONDIN 1; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ADD ON THERAPY; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; AORTA DISSECTION; ARTHRALGIA; BACKACHE; BONE METABOLISM; BONE METASTASIS; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOKALEMIA; LOW DRUG DOSE; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MYALGIA; MYELOID PROGENITOR CELL; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR DOWN REGULATION; RECTAL ULCER; REVIEW; RISK BENEFIT ANALYSIS; SEPSIS; SIDE EFFECT; SOLID TUMOR; VEIN THROMBOSIS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 84873865047     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31827e0b86     Document Type: Review

References (79)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
2. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358:2039-2049.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irino-tecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
4. US Food and Drug Administration. Prescribing information for AVASTIN\(bevacizumab), October 2012 update. Available at: http://www.accessdata. fda.gov/drugsatfda-docs/label/2012/125085s239lbl.pdf. Accessed November 2, 2012.
5. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for nonYsmall-cell lung cancer. N Engl J Med. 2006;355: 2542-2550.
6. Kreisl TN, Zhang W, Odia Y, et al. A phase II trial of single-agent bevaci-zumab in patients with recurrent anaplastic glioma. Neuro Oncol. 2011; 13:1143-1150.
7. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus inter-feron alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-2111.
8. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16-24.
9. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neu-roendocrine tumors. N Engl J Med. 2011;364:514-523.
10. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364: 501-513.
11. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134.
12. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase an-giogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of CancerVSoft Tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol. 2009;27:3126-3132.
13. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in meta-static carcinoma of the prostate. CA Cancer J Clin. 1972;22:232-240.
14. Stewart RJ, Panigrahy D, Flynn E, et al. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol. 2001;165:688-693.
15. Pallares J, Rojo F, Iriarte J, et al. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol Histopathol. 2006;21:857-865.
16. Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143: 401-409.
17. Tomic TT, Gustavsson H, Wang W, et al. Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang-2. Prostate. 2012;72:705-712.
18. George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res. 2001;7:1932-1936.
19. Antonarakis ES, Carducci MA. Targeting angiogenesis for the treatment of prostate cancer. Expert Opin Ther Targets. 2012;16:365-376.
20. Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30:1534-1540.
21. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593-4599.
22. Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001;61: 3369-3372.
23. Small AC, Oh WK. Bevacizumab treatment of prostate cancer. Expert Opin Biol Ther. 2012;12:1241-1249.
24. Di Lorenzo G, Figg WD, Fossa SD, et al. Combination of bevacizu-mab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol. 2008;54:1089-1094.
25. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357: 2666-2676.
26. Kozloff MF, Berlin J, Flynn PJ, et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology. 2010;78:329-339.
27. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242-245.
28. Chu QS. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther. 2009;9:263-271.
29. Dupont J, Schwartz LH, Koutcher J, et al. Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies [abstract 3009]. Proc Am Soc Clin Oncol Meeting. 2004;22:197s.
30. Massarelli E, Miller VA, Leighl NB, et al. Phase II study of he efficacy and safety of intravenous AVE0005 (VEGF Trap) given every 2 weeks in patients with platinum and erlotinib-resistant adenocarcinoma of lung [abstract 7627]. Proc Am Soc Clin Oncol. 2007;25:416s.
31. Tew WO, Colombo N, Ray-Coquard A, et al. VEGF Trap for patients with recurrent platinum-resistant epithelial ovarian cancer: preliminary results of a randomized Phase II study [abstract 5508]. Proc Am Soc Clin Oncol. 2007;25:276s.
32. Lockhart AC, Rothenberg ML, Dupont J, et al. Phase I study of intravenous vascular endothelial growth factor Trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol. 2010;28:207-214.
33. Tang P, Cohen SJ, Bjarnason GA, et al. PhaseII of aflibercept inpreviously treated patients with metastatic colorectal cancer: a Princess Margaret Hospital Phase II Consortium trial [abstract 4027]. Proc Am Soc Clin Oncol. 2008;26:184.
34. Hobday TJ, Rowland K, Dueck A, et al. N0537: a North Central Cancer Treatment Group (NCCTG) phase II study of VEGF Trap in patients with metastatic breast cancer previously treated with anthracycline and/or taxanes. Proc Breast Cancer Symp. 2008;167s. Abstract 164.
35. Van Cutsem E, Tabernero J, Lakomy R. Intravenous aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): results of a multinational phase III trial (EFC10262-VELOUR). Ann Oncol. 2011;22(suppl 5).
36. Sanofi-Aventis, LLC. Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP\(aflibercept). Press release [online] issued April 5, 2012. Available at: http://investor.regeneron.com/release-detail.cfm? releaseid=661995. Accessed October 3, 2012.
37. Petrillo M, Scambia G, Ferrandina G. Novel targets for VEGF-independent anti-angiogenic drugs. Expert Opin Investig Drugs. 2012;21:451-472.
38. Michaelson MD, Oudard S, Ou Y, et al. Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). Presented at the 2011 American Society of Clincal Oncology Annual Meeting; Chicago, IL; 2011. Abstract 4515.
39. Takeuchi K, Ito F. Receptor tyrosine kinases and targeted cancer therapeutics. Biol Pharm Bull. 2011;34:1774-1780.
40. Dahut WL, Scripture C, Posadas E, et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res. 2008;14:209-214.
41. Adelberg D, Karakunnel JJ, Gulley JL, et al. A phase II study of cediranib in post-docetaxel, castration-resistant prostate cancer (CRPC). Presented at the 2010 American Society of Clincal Oncology Genitourinary Cancers Symposium; San Francisco, CA; 2010. Abstract 63.
42. Dror Michaelson M, Regan MM, Oh WK, et al. Phase II study of suni-tinib in men with advanced prostate cancer. Ann Oncol. 2009;20: 913-920.
43. Shojaei F, Lee JH, Simmons BH, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 2010;70: 10090-10100.
44. Knudsen BS, Gmyrek GA, Inra J, et al. High expression of the MET receptor in prostate cancer metastasis to bone. Urology. 2002;60: 1113-1117.
45. Verras M, Lee J, Xue H, et al. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res. 2007;67:967-975.
46. Hussain M, Smith MR, Sweeney C, et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial. Presented at the 2011 American Society of Clinical Oncology Annual Meeting; Chicago, IL; 2011. Abstract 4516.
47. de Bono JS, Smith MR, Rathkopf D, et al. Cabozantinib (XL184) at 40 mg in patients with metastatic castration resistant prostate cancer (mCRPC): results of a phase 2 non-randomized expansion cohort (NRE). Presented at the European Society of Medical Oncology 2012 Congress; Vienna, Austria; 2012. Abstract 8970.
48. Isaacs JT, Pili R, Qian DZ, et al. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate. 2006;66:1768-1778.
49. Isaacs JT. The long and winding road for the development of tasquini-mod as an oral second-generation quinoline-3-carboxamide antiangio-genic drug for the treatment of prostate cancer. Expert Opin Investig Drugs. 2010;19:1235-1243.
50. Bjork P, Bjork A, Vogl T, et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quino-line-3-carboxamides. PLoS Biol. 2009;7:e97.
51. Cheng P, Corzo CA, Luetteke N, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med. 2008;205:2235-2249.
52. Murdoch C, Muthana M, Coffelt SB, et al. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8: 618-631.
53. Schmid MC, Varner JA. Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. J Oncol. 2010;2010:201026.
54. Olsson A, Bjork A, Vallon-Christersson J, et al. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer. 2010;9:107.
55. Antony L, Dalrymple S, Gerber S, et al. Tasquinimod suppresses the adaptive stress response within sites of prostate cancer via disrupting zinc-dependent histone deacetylase 4 signaling. Presented at the American Association for Cancer Research 103rd Annual Meeting; Chicago, IL; 2012. Abstract 4701.
56. Bratt O, Haggman M, Ahlgren G, et al. Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. Br J Cancer. 2009;101:1233-1240.
57. Pili R, Haggman M, Stadler WM, et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol. 2011;29:4022-4028.
58. Ng SS, MacPherson GR, Gutschow M, et al. Antitumor effects of tha-lidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. Clin Cancer Res. 2004;10:4192-4197.
59. Li H, Raia V, Bertolini F, et al. Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model. BJU Int. 2008;101:884-888.
60. Paravar T, Lee DJ. Thalidomide: mechanisms of action. Int Rev Immunol. 2008;27:111-135.
61. Galustian C, Dalgleish A. Lenalidomide: a novel anticancer drug with multiple modalities. Expert Opin Pharmacother. 2009;10:125-133.
62. Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol. 2004;22:2532-2539.
63. Ozkan M, Eser B, Er O, et al. Inhibition of angiogenesis: thalidomide or low-molecular-weight heparin? J Clin Oncol. 2005;23:2113. Author reply, 4.
64. Ning YM, Gulley JL, Arlen PM, et al. Phase II trial of bevacizu-mab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:2070-2076.
65. Moss RA, Mohile SG, Shelton G, et al. A phase I open-label study using lenalidomide and docetaxel in androgen independent prostate cancer (AIPC). Presented at the 2007 American Society of Clinical Oncology Genitourinary Cancers Symposium; Orlando, FL; 2007. Abstract: 89.
66. Dreicer R, Garcia J, Smith S, et al. Phase I/II trial of GM-CSF and lena-lidomide in patients with hormone refractory prostate cancer (HRPC). Presented at the 2007 American Society of Clinical Oncology Annual Meeting; Chicago, IL; 2007. Abstract 15515.
67. Garcia JA, Triozzi P, Elson P, et al. Clinical activity of ketoconazole and lenalidomide in castrate progressive prostate carcinoma (CPPCA): preliminary results of a phase II trial. Presented at the 2008 American Society of Clinical Oncology Annual Meeting; Chicago, IL; 2008. Abstract 5143.
68. Petrylak DP, Fizazi K, Sternberg C, et al. A phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone (DP) with or without lenalidomide (LEN) in patients with castrate-resistant prostate cancer (CRPC): the MAINSAILTrial. Presented atthe European Society of Medical Oncology 2012 Congress; Vienna, Austria; 2012. Abstract LBA24.
69. Keizman D, Zahurak M, Sinibaldi V, et al. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin Cancer Res. 2010;16:5269-5276.
70. Chong CR, Sullivan DJ Jr. New uses for old drugs. Nature. 2007;448: 645-646.
71. Chong CR, Xu J, Lu J, et al. Inhibition of angiogenesis by the anti-fungal drug itraconazole. ACS Chem Biol. 2007;2:263-270.
72. Xu J, Dang Y, Ren YR, et al. Cholesterol trafficking is required for mTOR activation in endothelial cells. Proc Natl Acad Sci USA. 2010; 107:4764-4769.
73. Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used anti-fungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17:388-399.
74. Antonarakis ES, Heath EI, Smith DC, et al. A noncomparative randomized phase II study of two dose levels of itraconazole in men with meta-static castration-resistant prostate cancer (mCRPC): a DOD/PCCTC trial. Presented at the 2011 American Society of Clinical Oncology Annual Meeting; Chicago, IL; 2011. Abstract 4532.
75. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148-1159.
76. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated nonYsmall-cell lung cancer. N Engl J Med. 2005;353: 123-132.
77. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361: 947-957.
78. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735-742.
79. Lambrechts D, Claes B, Delmar P, et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol. 2012;13:724-733.